To overcome this, Manna et al. developed a nanovaccine approach that utilizes a potent toll-like receptor 7/8 (TLR7/8) agonist in combination with a peptide that activates the NLRP3 inflammasome that self-assembles into nanoparticles that can be readily formulated with antigens targeting specific cancers [114]. Here, TLR7 is linked to cancer.